SOURCE: Health Enhancement Products, Inc

November 10, 2010 13:56 ET

Health Enhancement Products, Inc. Finalizes Due Diligence With Zus Health, LLC

Company Receives Initial Payment and Will Begin Product Fulfillment

SCOTTSDALE, AZ--(Marketwire - November 10, 2010) - Health Enhancement Products, Inc., (OTCBB: HEPI) announced today that its due diligence period with Zus Health, LLC (Zus) has been completed and the Company is moving forward to the next stage of its previously announced agreement.

The Company recently signed a licensing and distribution agreement with Zus Health for worldwide sales & marketing rights to its proprietary nutraceutical, ProAlgaZyme® (PAZ™) which included a due diligence and option period. The agreement is now in full effect and both parties are engaging in product launch activities. An upfront payment of $255,000 was made to HEPI today. In return HEPI will license its proprietary algal extract to Zus effective immediately. In addition to the upfront payment, the agreement calls for monthly orders that increase as production capabilities are enhanced. 

Brad Robinson, Zus Health Chairman, stated, "We've completed our due diligence and scientific review of the benefits of PAZ™. We are excited to bring PAZ™ to market as it has shown such promise in improving Cholesterol levels and offers additional health benefits. It's our intent to immediately begin our marketing efforts and build orders across sales channels worldwide for PAZ™."

"We want to ensure that as we begin to deliver our product to a mass audience that PAZ retains its unique beneficial effects, even as production volume exponentially grows," stated HEPI director and board member John Gorman. "To this extent, we've enlisted the help of well-regarded scientists, including algal physiologist Dr. Barry Rosen, to ensure that we maintain culture integrity and stability of PAZ™." Mr. Gorman continued, "We recognize this has been a long process but are confident, as are our partners, that we are taking the necessary steps to prove the value of our proprietary PAZ™ compound."

The Company also announced it has contracted the Bigelow Laboratories Center for Ocean Sciences to conduct genomics tests and culturing studies to help maintain and enhance the Company's proprietary stock of algae cultures.

"We will continue to improve productivity and efficacy," Gorman continued. "HEPI has a great opportunity to break out and build tremendous volume based on our current research and findings."

About Health Enhancement Products, Inc.
Health Enhancement Products, Inc. (OTCBB: HEPI) is a health & wellness company engaged in the development of a product comprised of pure, all-natural compounds that can be used as a dietary supplement and food additive. The Company's product is ProAlgaZyme® (PAZ™), a liquid product drawn from living algae grown in purified water. The water in which the algae are grown is drawn off, filtered and bottled under the trademark ProAlgaZyme®.

About Zus Health, LLC
Zus Health, LLC., specializes in manufacturing and distributing only the highest quality nutraceuticals worldwide, through numerous distribution channels.

Safe Harbor Statement
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.

Contact Information

  • IR Contact:

    David Sasso